RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S
RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedixTM,
a Targeted Alpha Therapy for patients with neuroendocrine tumors
RadioMedix Selected for National Cancer Institute’s Investor Initiatives and Presentation at BIO Investor Forum
Extended partnership between Radiomedix INC and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America
RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedixTM, a Targeted Alpha Therapy for patients with neuroendocrine tumors
Extended partnership between Radiomedix Inc and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America
RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors
RadioMedix, Inc., received an exclusive distributions rights for SEDECAL Preclinical PET-CT and PET-MR systems in North America.
The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance
RadioMedix and AREVA Med - SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.
RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)
RadioMedix Successful Installations of SmartMedixTM and AIO fully automated synthesizer modules in USA.
AREVA Med and RadioMedix partner to develop new treatment against Neuroendocrine Tumors
NIH NCI SBIR Contract Award for targeted alpha-TAT of metastatic melanoma. The third collaborative grant for RadioMedix and Viewpoint.
RadioMedix initiates the first Ga-68 PSMA (ProstaMedix™) clinical trial for diagnosis and management of prostate cancer in U.S.
Radiomedix Receives Phase I SBIR Funding from the NCI for Metastatic Melanoma Theranostics
Dr. Tworowska selected as 2013 U.S. IUPAC and UNSC Young Observer and recipient the Travel Award for the IUPAC Congress
RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radiopharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radiolabeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.
RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.